Experienced in Primary Lymphoma of the Brain

Dr. Carolina D. Schinke

Hematology Oncology | Hematology | Oncology
University Of Arkansas For Medical Sciences
4301 W Markam St, 
Little Rock, AR 
Accepting New Patients
Offers Telehealth
Experienced in Primary Lymphoma of the Brain
University Of Arkansas For Medical Sciences
4301 W Markam St, 
Little Rock, AR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carolina Schinke is a Hematologist Oncology specialist and a Hematologist in Little Rock, Arkansas. Dr. Schinke is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant. Dr. Schinke is currently accepting new patients.

Her clinical research consists of co-authoring 134 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AR
Hospital Affiliations
Uams Medical Center
Languages Spoken
English
German
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES
4301 W Markam St, Little Rock, AR 72205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Study Phase: Phase 2
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drugs: M-VTD-PACE, TT3-LITE Regimen (L-TT3)
Study Phase: Phase 3
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Drug, Device
Study Drug: MEL-CFZ-TD-PACE
Study Phase: Phase 2
Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients
Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 19, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of a Novel Proteasome/IMiD Combination, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Patients
A Phase II Trial of a Novel Proteasome/IMiD Combination, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Patients
Enrollment Status: Withdrawn
Publish Date: January 23, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

134 Total Publications

Stem cell boost for immune effector cell associated hematotoxicity in multiple myeloma: minimizing long-term complications and expanding post CAR T-cell therapy relapse options.
Stem cell boost for immune effector cell associated hematotoxicity in multiple myeloma: minimizing long-term complications and expanding post CAR T-cell therapy relapse options.
Journal: Expert review of hematology
Published: October 04, 2025
Similar Doctors
Advanced in Primary Lymphoma of the Brain
Dr. Thomas Sneed
Hematology | Oncology
Advanced in Primary Lymphoma of the Brain
Dr. Thomas Sneed
Hematology | Oncology

Central Arkansas Radiation Therapy Institute Inc

1505 N Medical Dr, 
Stuttgart, AR 
 (46.2 miles away)
501-906-3000
Languages Spoken:
English
See accepted insurances

Thomas Sneed is a Hematologist and an Oncologist in Stuttgart, Arkansas. Dr. Sneed is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Breast Cancer, Small Lymphocytic Lymphoma (SLL), Colorectal Cancer, Lynch Syndrome, and Bone Marrow Aspiration.

Advanced in Primary Lymphoma of the Brain
Dr. Appalanaidu Sasapu
Hematology | Oncology
Advanced in Primary Lymphoma of the Brain
Dr. Appalanaidu Sasapu
Hematology | Oncology

Central Arkansas Radiation Therapy Institute Inc

8901 Carti Way, 
Little Rock, AR 
 (3.0 miles away)
501-906-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Appalanaidu Sasapu is a Hematologist and an Oncologist in Little Rock, Arkansas. Dr. Sasapu is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Thrombocytopenia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Primary Lymphoma of the Brain
Dr. Sue Tsuda
Oncology | Hematology
Advanced in Primary Lymphoma of the Brain
Dr. Sue Tsuda
Oncology | Hematology

American Oncology Partners PA

350 Salem Rd, Suite 4, 
Conway, AR 
 (24.6 miles away)
501-327-2995
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sue Tsuda is an Oncologist and a Hematologist in Conway, Arkansas. Dr. Tsuda is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Lung Cancer. Dr. Tsuda is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schinke's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile